Endometriosis and ovarian cancer: A review

Nikolaos Vlahos, Nikos F Vlahos, Theodoros Kalampokas, Stylianos Fotiou
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2009 · vol. 26(3) , pp. 1–7 · doi:10.1080/09513590903184050 · PMID:19718562 · W1986581584
review OA: closed CC0 ⤵ 42 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This review of clinical, epidemiologic, and molecular literature describes shared predisposing factors, similar growth and resistance mechanisms, and common ovarian cancer subtypes associated with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This work is a review titled “Endometriosis and ovarian cancer: A review,” but the provided text contains only publisher/platform and general informational content rather than the scientific review’s study design, methods, or findings. Because no substantive content from the review is included here, key results, scope, and explicitly stated limitations cannot be determined from the supplied excerpt. Relevance to endometriosis: the title indicates the review addresses endometriosis alongside ovarian cancer, though the actual cited evidence or conclusions are not present in the provided text. This paper is centrally about endometriosis — its title frames a review linking endometriosis with ovarian cancer.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVES: To describe the relationship between endometriosis and ovarian cancer. SEARCH STRATEGY: Review of the relevant clinical, epidemiologic, and molecular biology literature. SELECTION CRITERIA: Studies published in the English language using the MEDLINE database. DATA COLLECTION AND ANALYSIS: Relevant studies were reviewed by the three authors and those that seem to be of significant scientific value, based on the methodology and statistical power, were included. MAIN RESULTS: Endometriosis and ovarian cancer share many common predisposing factors. Both conditions demonstrate similar patterns regarding local invasion and distal spread they respond similarly to estrogen-induced growth signaling, they express resistance to apoptotic mechanisms and they are characterized by genomic instability. Endometrioid and clear-cell are the most frequent types of ovarian cancer associated with endometriosis. Tubal ligation, in women with endometriosis, seems to prevent retrograde menstruation but it has also been shown to be protective from these types of ovarian cancer. CONCLUSION: There is evidence to support that endometriosis (by definition a benign process), could simultaneously have the potential for malignant transformation. More studies are needed to establish risk factors that may lead to malignant transformation of this condition and to identify predisposed individuals who may require closer surveillance.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Endometriosis Endometriosis Endometriosis Endometriosis Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Female Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (55)

Cited by (42)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:59.677786+00:00
License: CC0 · commercial use OK